Blocks revival rolls on with £115m Syncona sale

Risk appetite in the equity blocks market in Europe has improved significantly, according to market sources, and a UK biomedical research charity is the latest vendor to take advantage of the better conditions by offloading a chunk of its stake in Syncona, the FTSE 250 life sciences investment company.